NCT05210790Phase 3Active not recruiting

A Study of Rusfertide in Adults With Polycythemia Vera (PV)

Study sponsor: Protagonist Therapeutics, Inc. · PTGX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2025-02-21Actual
Enrollment · participants293Actual
Source updated2026-10-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects achieving a response who receive rusfertide compared to placebo. Description: Response is defined as absence of phlebotomy eligibility. Time frame: Week 20 through Week 32. After: Measure: Part 1a: Percentage of Participants Who Achieved Response Description: Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%. Time frame: From Weeks 20 to 32.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview